• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center
ShangPharma and Qidong Biopharma Industrial Zone sign an agreement for a 60 million USD investment in China

ShangPharma and Qidong Biopharma Industrial Zone sign an agreement for a 60 million USD investment in China

Sep 22, 2015 | Uncategorized |

SHANGHAI, Sept. 17, 2015/PRNewswire— ShangPharma announced its plans to establish a subsidiary in the Qidong Biopharma Industrial Zone as part of a multistage expansion project for its biologics service portfolio. In the first phase, ShangPharma and Qidong Biopharma Industrial zone will invest 60 million USD to build a comprehensive and multifunctional pre-clinical research facility as well as a state-of-the-art biologics manufacturing facility.  The Preclinical facility will be operated by ShangPharma’s CRO division, ChemPartner and the Biologics manufacturing facility will be operated by ShangPharma’s CMO division, China Gateway Biologics.  During the construction phase of the manufacturing facility, the company’s existing biologics CMC facility will continue to operate out of its Shanghai site.

The new China Gateway Biologics’ manufacturing facility will provide commercial scale operations for biopharmaceuticals.  It will be comprised of one 500L single-use mammalian cell culture train for clinical phase supply and two 2000L trains for commercial manufacturing. These capabilities will be complemented with fill & finish capabilities of the appropriate scale.

Michael Hui, CEO of ShangPharma stated, “I am proud that Qidong Biopharma Industrial Zone has selected ShangPharma as partner for the first facility of this kind in Qidong. The investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale. We strongly believe the state-of-the-art single use facility conforming to Western standards will be able to support our international client base.”

Xu Feng, Qidong’s Party Secretary and Chairman of Qidong Standing Committee of the People’s Congress said, “Choosing ShangPharma as the first tenant for the biopharma zone in Qidong is a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai.  ShangPharma/CGB is a strong partner with international focus and the facility will serve as model for other projects of similar scale and needs.”

The biopharmaceutical manufacturing facility shall be operational for the first client project in early 2018.

About ShangPharma
ShangPharma is comprised of a family of companies including China Gateway Biologics, China Gateway Pharmaceutical Development, ChemPartner, ShangPharma Technology and ShangPharma Investment. The group is actively investing, licensing, and forming partnerships to better serve the healthcare industry. ShangPharma aims, through all its divisions, to create an ecosystem that allows close interaction between major hospitals and academic centers, by matching them with pharmas, biotech, and research institutes to enable the success of all.

About China Gateway Biologics
China Gateway Biologics is a full service provider of biologics manufacturing for the biopharmaceutical industry. It serves both Chinese domestic and international client base from preclinical to commercial scale in China with Western standards.

About ChemPartner
ChemPartner is a leading contract research organization providing high-quality and cost-effective services for the global pharmaceutical and biotechnology industry.  The company offers a broad range of   integrated services across the drug discovery and development process.  ChemPartner’s services consist of discovery biologics, discovery chemistry, discovery biology and preclinical development.

For more information about ShangPharma and its subsidiaries, visit www.ShangPharma.com – This link opens in a new window.

CONTACT:
Ms. Jin Qin
Building 5, 998 Halei Road,
Zhangjiang Hi-tech Park, Pudong
Shanghai, China. 201203
Tel: +86 21 5132 0220
jqin@shangpharma.com

Tags: QidongShanghai
0
Share

You also might be interested in

2015 Qidong Science and Technology Festival

2015 Qidong Science and Technology Festival

Oct 9, 2015

ShangPharma Biopharmaceutical Innovation and Development Forum is going to begin[...]

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

Jun 22, 2016

The 18th International Forum on Biotechnology & Pharmaceutical Industry (Bio-Forum)[...]

Latest News

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities

06/11/2020

Shanghai, China (June 9, 2020) – Shanghai ChemPartner...

ChemPartner Assists the Mount Sinai Health System in Producing Reagent for COVID-19 Research

05/12/2020

Shanghai, China (May 12, 2020) – Shanghai ChemPartner...

ChemPartner and the Gladstone Institutes Announce COVID-19 Research Collaboration

04/17/2020

SAN FRANCISCO, Calif. and SHANGHAI, China. (April 15, 2020)...

ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai

04/02/2020

Shanghai, China (March 17, 2020) – Shanghai ChemPartner...

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

12/18/2019

Shanghai, China (December 17, 2019) – Shanghai ChemPartner...

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

07/19/2019

Contract manufacturers play a significant role when it comes...

Tag Cloud

2017 AACR Agreement Antibody Engineering art Berkeley Lights Best Life Science BIOtech Blend Boston Capital Market Chemistry ChemPartner Congratulates CPhI CPSA Shanghai 2016 CRO DMPK Exploratory Toxicology Labs layout Merger Deal PEGS PEGS CHINA Peptide Pharma Pharmacology product PTF Qidong Quantum Hi-Tech China Biological Research Facility San Diego San Francisco Shanghai Shanghai ChemPartner ShangPharma Sponsor Strategic Corporate Restructuring Tarveda Therapeutic Top 10 CMOs Vice President World ADC

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • Shanghai ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2021 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend
Prev Next